Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis

NCT00698334 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections
Acquired Immunodeficiency Syndrome
Tuberculosis

Interventions

DRUG: INH, Rifampicin, Ethambutol and Pyrazinamide
DRUG: INH, Rifampicin, Ethambutol and Pyrazinamide

Sponsor

All India Institute of Medical Sciences

Collaborators

[object Object]